You've no doubt heard a lot about the COVID-19 vaccines from Pfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA) that millions of Americans have already received. However, the advances in fighting the pandemic aren't limited to just vaccines. In this Motley Fool Live video recorded on Feb. 1, 2021, "The Wrap" host Jason Hall and Motley Fool contributors Keith Speights and Danny Vena discuss one big COVID-19 story that has nothing to do with vaccines.

毫无疑问，你已经从辉瑞(NYSE:PFE)和Moderna(NASDAQ:MRNA)那里听说了许多关于COVID-19疫苗的消息，数百万美国人已经接受了这些疫苗。然而，抗击大流行的进展不仅限于疫苗。在这段录制于2021年2月1日的视频中，The Wrap主持人Jason Hall和撰稿人Keith Speights和Danny Vena讨论了一个与疫苗无关的COVID-19大新闻。

Danny Vena: So I guess the last question here is, are there other big stories out there on the COVID front. Things that are going on that maybe we don't know about or things that we should perhaps keep an eye on.

丹尼·维纳:我想最后一个问题是，在新冠肺炎疫情方面还有其他重大事件吗?一些我们不知道的事情或者一些我们应该关注的事情。

Keith Speights: Yeah. There's one really, I think a big story that may be not quite as big as Johnson and Johnson's and Novavax's news, but it's up there.

基斯Speights:是的。我认为有一个大新闻可能不像强生和诺瓦瓦克斯的新闻那么大，但它在那里。

Regeneron(NASDAQ:REGN) last week announced results, interim results from earlier results for late-stage study of an antibody cocktail, and they were using this cocktail to prevent COVID infection in people who have been exposed to it. People who are living in a household where one of their family members did have COVID. They hadn't been diagnosed with it yet, but they received this antibody cocktail as prophylaxis.

Regeneron公司上周公布了一项抗体鸡尾酒疗法的中期研究结果，他们正在使用这种鸡尾酒疗法预防接触过这种抗体的人感染新冠病毒。家庭成员中有一人感染了新冠病毒的人。他们还没有被诊断出患有这种病，但他们接受了这种混合抗体作为预防。

Now here's the cool thing. It prevented 100 percent of symptomatic infection. Basically, no one taking this antibody cocktail developed symptomatic COVID-19. Zero.

这是很酷的事情。它能百分之百防止有症状的感染。基本上，服用这种抗体混合物的人没有出现COVID-19症状。零。

Danny Vena: That's impressive.

丹尼·维纳:真令人印象深刻。

Keith Speights: We're talking about I think 186 participants. None of them developed COVID-19 and they've been exposed to it. All right.

Keith Speights:我想我们谈论的是186名参与者。他们中没有人感染COVID-19，也没有人接触过。好吧。

Jason Hall: Known exposures, that's is the thing.

杰森·霍尔:这就是问题所在。

Keith Speights: Known exposures. Yeah. Regeneron's referring to this as passive vaccination. This isn't a vaccine, it's an antibody therapy. But it's very encouraging, and now about 50 percent, about half of the participants who took it did get infected. But it was asymptomatic infection and it went away in no more than a week.

Keith Speights:已知的暴露。是的。Regeneron认为这是被动疫苗接种。这不是疫苗，这是抗体疗法。但这是非常鼓舞人心的，现在大约有50%，大约一半的参与者确实感染了病毒。但这是一种无症状感染，不到一周就消失了。

To me, this is very encouraging. Now they're not going to have their final results, I think until maybe March or something like that, but this is something to really watch out for because it's an injection, and if everything continues to go well, in this study, we could see a very promising antibody cocktail on the market maybe by spring or summer. That could be very useful for folks who maybe haven't been vaccinated yet but have been exposed to COVID

对我来说，这是非常鼓舞人心的。现在他们不会有最后的结果,我认为也许直到3月之类的,但是这是真的当心因为它是注射,如果继续一切顺利,在这项研究中,我们可以看到一个非常有前途的抗体鸡尾酒市场上也许春季或夏季。这对那些可能还没有接种过疫苗但已经接触过COVID - 19的人非常有用

Danny Vena: Just a quick follow up. What does that mean exactly, antibody cocktail versus vaccination. I'm not medically inclined.

丹尼·维纳:我再问一个问题。这到底是什么意思，抗体鸡尾酒对抗疫苗。我不擅长医学

Keith Speights: Sure. Let's just say what vaccines do Danny is they, well I want to take Moderna's vaccine as an example. But all the vaccines use a similar concept even though their approaches vary. Their idea is to make the body produce antibodies in response to what it thinks as the virus.

基斯Speights:当然。我们来看看疫苗的作用，我想以Moderna的疫苗为例。但是所有的疫苗都使用相似的概念，尽管它们的方法不同。他们的想法是让身体产生抗体来应对它认为是病毒的东西。

In Moderna's case and Pfizer's case, what they do is they put messenger RNA in the cells that tell the ribosomes to build proteins that are identical to the spike protein that occurs on the surface of the coronavirus. It just causes the body to mount that immune response.

在Moderna和辉瑞的案例中，他们所做的是将信使RNA放入细胞中，告诉核糖体制造与冠状病毒表面的刺突蛋白相同的蛋白质。它只会导致身体产生免疫反应。

What these antibody therapies are is they actually inject antibodies. They don't cause your body to produce antibodies, they put the antibodies into your body. Those antibodies fight the virus. That's the main difference between them. So Regeneron's isn't technically a vaccine, but it's accomplishing a similar goal as a vaccine.

这些抗体疗法实际上是注射抗体。它们不会使你的身体产生抗体，而是将抗体注入你的身体。这些抗体对抗病毒。这是它们之间的主要区别。所以Regeneron从技术上讲并不是一种疫苗，但它实现了与疫苗类似的目标。